Amylx Pharmaceuticals Inc vs Ryanair Holdings plc — how do they compare? Amylx Pharmaceuticals Inc trades at $23.96 (market cap $2.64B), while Ryanair Holdings plc trades at $60.03 (market cap $29.63B). The key difference: Ryanair Holdings plc is far larger — about 11.2× Amylx Pharmaceuticals Inc's market cap, and Ryanair Holdings plc pays a 1.51% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | RYAAY | |
|---|---|---|
Market Cap | $2.64B | $29.63B |
Sector | Health | Industrials |
52-Week High | $24.19 | $73.82 |
52-Week Low | $7.82 | $53.24 |
Enterprise Value | $2.39B | $26.61B |
Dividend Yield | — | 1.51% |
Trailing returns across standard periods
Latest headlines on both assets
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →